For atezolizumab, the phase II clinical trial BIRCH has also demonstrated atezolizumab monotherapy was associated with good tolerability and efficacy in patients with PD-L1-selected advanced NSCLC across lines of therapy, especially in PD-L1 TC3/IC3 patients (16). The gene discussed is CD274; the disease is non-small cell lung carcinoma.